CanSino Biologics (SHA:688185, HKG:6185) received a drug registration certificate for its ACYW135 Meningococcal Polysaccharide Conjugate Vaccine from Indonesia's drug regulator, a Monday bourse filing said.
The vaccine is indicated for the prevention of epidemic cerebrospinal meningitis in infants and children aged three months to three years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments